Claudin 18 (43–14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapyRiley J. Arseneau, Thomas Arnason, Boris Gala-López et al.|Translational Oncology|2025Cited by 11
Peri-tumoural lymphocyte neighbourhoods predict longer survival in pancreatic ductal adenocarcinomaRiley J. Arseneau, Jeanette E. Boudreau, Stacey N. Lee et al.|Frontiers in Immunology|2025Cited by 3
Barriers to accessing healthcare services: A multidisciplinary approach towards improving pancreatic cancer survival in a Canadian province.Elizabeth Faour, Ravi Ramjeesingh, Bruce Colwell et al.|Journal of Clinical Oncology|2019Cited by 0
Abstract B028: Claudin-18 expression (using the 43-14A antibody kit) in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for immunotherapy with zolbetuximabRiley J. Arseneau, Thomas Arnason, Boris Gala-López et al.|Cancer Immunology Research|2024Cited by 0
Peri-tumoural lymphocyte neighbourhoods predict longer survival in pancreatic ductal adenocarcinomaRiley J. Arseneau, Jeanette E. Boudreau, Jorge P Meija et al.|medRxiv|2025Cited by 0